Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683205 | 0.86 | ALDH1A1 (0.46) | ERN1ALDH1A1KMT2ATXNRD1TXNRD3 | |
| SCHEMBL7694234 | 0.82 | ERN1 (0.57) | ERN1ALDH1A1KMT2ATXNRD1TXNRD3 | |
| SCHEMBL27985725 | 0.79 | ERN1 (0.54) | ERN1ALDH1A1KMT2ATXNRD1TXNRD3 | |
| SCHEMBL11215635 | 0.79 | ERN1 (0.57) | ERN1ALDH1A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL16306939 | 0.79 | ERN1 (0.57) | ERN1ALDH1A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL2117435 | 0.79 | ERN1 (0.57) | ERN1ALDH1A1KMT2ATXNRD1TXNRD3 | |
| SCHEMBL3067225 | 0.78 | ERN1 (0.53) | ERN1ALDH1A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL6556637 | 0.78 | ALDH1A1 (0.49) | ALDH1A1KMT2ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL6556669 | 0.78 | PDE7A (0.56) | ALDH1A1KMT2ATXNRD1TXNRD3TXNRD2 | |
| SCHEMBL2917511 | 0.78 | ALDH1A1 (0.49) | ALDH1A1KMT2ATXNRD1TXNRD3TXNRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718849-B2 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2017-08-01 | — | — | US | disclosed |
| US-20140155511-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2014-06-05 | — | — | US | disclosed |
| EP-2061756-B1 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8513151-B2 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IS) | 2013-08-20 | — | — | US | disclosed |
| US-8420830-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8222453-B2 | Benzamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222453-B2 | Benzamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-09 | — | — | US | disclosed |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-09 | — | — | US | disclosed |
| US-20090156766-A1 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2009-06-18 | — | — | US | disclosed |
| EP-2061756-A2 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007146719-A2 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENYLACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1856096-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156766-A1 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | TST, MPST, NISCH | ERN1 1829/4885ALDH1A1 3167/4885KMT2A 4178/4885 |
| US-20140155511-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | C1S, SCO2, AP1S1 | ERN1 2197/4885ALDH1A1 3715/4885KMT2A 3469/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | ERN1 967/4885ALDH1A1 2963/4885KMT2A 2453/4885 |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | ERN1 969/4885ALDH1A1 3804/4885KMT2A 860/4885 |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F8 | ERN1 1998/4885ALDH1A1 2361/4885KMT2A 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.